Pesquisas alternativas:
liver thle2 » liver three (Expandir a Pesquisa)
doses liver » does liver (Expandir a Pesquisa), dose liver (Expandir a Pesquisa), doses given (Expandir a Pesquisa)
does devel » does level (Expandir a Pesquisa), does deep (Expandir a Pesquisa), does novel (Expandir a Pesquisa)
devel ther » novel ther (Expandir a Pesquisa), level theory (Expandir a Pesquisa), develop them (Expandir a Pesquisa)
drug doses » drug disease (Expandir a Pesquisa)
drug does » drugs does (Expandir a Pesquisa), drug de (Expandir a Pesquisa), drug diet (Expandir a Pesquisa)
drug dose » drug dosage (Expandir a Pesquisa)
dose live » dose level (Expandir a Pesquisa)
live ther » live them (Expandir a Pesquisa), live rather (Expandir a Pesquisa), liver other (Expandir a Pesquisa)
liver thle2 » liver three (Expandir a Pesquisa)
doses liver » does liver (Expandir a Pesquisa), dose liver (Expandir a Pesquisa), doses given (Expandir a Pesquisa)
does devel » does level (Expandir a Pesquisa), does deep (Expandir a Pesquisa), does novel (Expandir a Pesquisa)
devel ther » novel ther (Expandir a Pesquisa), level theory (Expandir a Pesquisa), develop them (Expandir a Pesquisa)
drug doses » drug disease (Expandir a Pesquisa)
drug does » drugs does (Expandir a Pesquisa), drug de (Expandir a Pesquisa), drug diet (Expandir a Pesquisa)
drug dose » drug dosage (Expandir a Pesquisa)
dose live » dose level (Expandir a Pesquisa)
live ther » live them (Expandir a Pesquisa), live rather (Expandir a Pesquisa), liver other (Expandir a Pesquisa)
1
“... are constantly under pressure, higher percentages of drugs are demanded, and the drug-discovery process is a...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
2
3
“... in part 2). Comparison of the PK and safety of each drug alone with those of the drugs in combination...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
4
Por Guerrero-Orriach, Jose Luis, Escalona Belmonte, Juan Jose, Ramirez Fernandez, Alicia, Ramirez Aliaga, Marta, Rubio Navarro, Manuel, Cruz Mañas, Jose
Publicado no Drug Des Devel Ther (2017)
“... is related to the dose-dependent signal, while the degree of protection is related to the concentration...”Publicado no Drug Des Devel Ther (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
6
Por Wang, Ying, Sun, Sheng-Gang, Zhu, Sui-Qiang, Liu, Chun-Feng, Liu, Yi-Ming, Di, Qing, Shang, Hui-Fang, Ren, Yan, Xiang, Wei, Chen, Sheng-Di
Publicado no Drug Des Devel Ther (2016)
“... for Parkinson’s disease (PD). A critical dose level above which a better benefit-to-harm ratio exists has not been...”Publicado no Drug Des Devel Ther (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
7
“..., BMI, drug dose and time from drug intake were recorded. RESULTS: All patients had a measurable...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
8
Por Gahr, Maximilian, Kölle, Markus A, Schönfeldt-Lecuona, Carlos, Lepping, Peter, Freudenmann, Roland W
Publicado em 2011
“... pharmacological profile, including single dosing, predominantly renal excretion, low drug–drug interaction risk...”Publicado em 2011
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
9
“..., resulting in a drug-antibody ratio of 2. In biodistribution studies, SIP(F8)-SS-DM1 accumulated in the tumor...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
10
11
Por Kosilov, Kirill Vladimirovich, Loparev, Sergey, Kuzina, Irina, Shakirova, Olga, Zhuravskaya, Nataliya, Lobodenko, Alexandra
Publicado no Ther Adv Urol (2016)
“... in antimuscarinic (AM) drug treatment. BACKGROUND: The prevalence of urge urinary incontinence (UUI) is an average...”Publicado no Ther Adv Urol (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
12
Por Erkılıç, E, Kesimci, E, Alaybeyoğlu, F, Kılınç, I, Tural, R, Yazgan, A, Gümüş, T, Sepici Dinçel, A, Dumlu, EG, Kanbak, O
Publicado no Drug Des Devel Ther (2017)
“... after reperfusion, and 6 hours after the surgical procedure (T0, T1, T2, and T3, respectively). RESULTS...”Publicado no Drug Des Devel Ther (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
13
Por Begoña Porteiro, Marcos F. Fondevila, Xabier Buque, Maria J. Gonzalez-Rellan, Uxia Fernandez, Alfonso Mora, Daniel Beiroa, Ana Senra, Rosalia Gallego, Johan Fernø, Miguel López, Guadalupe Sabio, Carlos Dieguez, Patricia Aspichueta, Rubén Nogueiras
Publicado em 2018-02-01
“... in the liver and in two human hepatic cells lines (HepG2 and THLE2). Results: The attenuation of liver damage...”Publicado em 2018-02-01
Obter o texto integral
Artigo
14
“... given for missing drugs were 9(27.3%) running out of medication/drug, 7(21.2%) being away from home...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
15
Por Djobet, M. P. Ngogang, Singhe, David, Lohoue, Julienne, Kuaban, Christopher, Ngogang, Jeanne, Tambo, Ernest
Publicado no AIDS Res Ther (2017)
“.... ARVs drugs samples included Nevirapine, Efavirenz, and fixed dose combinations of Zidovudine...”Publicado no AIDS Res Ther (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
16
Por Vornov, James J., Wozniak, Krystyna M., Wu, Ying, Rojas, Camilo, Rais, Rana, Slusher, Barbara S.
Publicado em 2013
Assuntos:
“...Drug Discovery and Translational Medicine...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
17
Por Goláň, Lubor, Goker-Alpan, Ozlem, Holida, Myrl, Kantola, Ikka, Klopotowski, Mariusz, Kuusisto, Johanna, Linhart, Aleš, Musial, Jacek, Nicholls, Kathleen, Gonzalez-Rodriguez, Derlis, Sharma, Reena, Vujkovac, Bojan, Chang, Peter, Wijatyk, Anna
Publicado no Drug Des Devel Ther (2015)
“...PURPOSE: Efficacy and safety of agalsidase alfa at 0.2 mg/kg weekly were compared with 0.2 mg/kg...”Publicado no Drug Des Devel Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
18
“... therapies. Kinases are one of the most common drug targets with a potential for cancer therapy. Cell cycle...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
19
Por Yovich, John L, Alsbjerg, Birgit, Conceicao, Jason L, Hinchliffe, Peter M, Keane, Kevin N
Publicado no Drug Des Devel Ther (2016)
“... the protocols. The live birth productivity rates exceeded 50% for women <35 years and was 33.2% for the group...”Publicado no Drug Des Devel Ther (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
20
Por Nygaard, Haakon B, Wagner, Allison F, Bowen, Garrett S, Good, Susan P, MacAvoy, Martha G, Strittmatter, Kurt A, Kaufman, Adam C, Rosenberg, Brian J, Sekine-Konno, Tomoko, Varma, Pradeep, Chen, Kewei, Koleske, Anthony J, Reiman, Eric M, Strittmatter, Stephen M, van Dyck, Christopher H
Publicado no Alzheimers Res Ther (2015)
“... at doses of 50 mg, 100 mg, 125 mg, or placebo daily for 4 weeks. The drug:placebo ratio was 3:1. Primary...”Publicado no Alzheimers Res Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo